← All Adaptive Biotechnologies CORP filings

Adaptive Biotechnologies CORP 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

NASDAQ
ADPT
Adaptive Biotechnologies CORP
10-Q: Adaptive Biotechnologies Reports Q1 2026 Results, Revenue Up 35%
Adaptive Biotechnologies Corporation announced its first quarter 2026 financial results, showcasing a 35% year-over-year revenue increase driven by strong performance in its MRD business.
NASDAQ
ADPT
Adaptive Biotechnologies CORP
10-Q: Adaptive Biotechnologies Reports Q3 Profit, Boosted by Genentech Termination
Adaptive Biotechnologies achieved net income in Q3 2025, driven by strong MRD revenue growth and a one-time revenue recognition from the Genentech collaboration termination.
NASDAQ
ADPT
Adaptive Biotechnologies CORP
10-Q: Adaptive Biotechnologies Reports Strong Q2 Revenue Growth
Adaptive Biotechnologies reported significant revenue growth and reduced net losses in its latest quarterly filing, driven by strong performance in its MRD business and increased clonoSEQ test volumes.
NASDAQ
ADPT
Adaptive Biotechnologies CORP
10-Q: Adaptive Biotechnologies Reports Q1 2025 Results: Revenue Climbs, Losses Narrow
Adaptive Biotechnologies' Q1 2025 shows revenue growth driven by MRD, alongside reduced operating losses.
NASDAQ
ADPT
Adaptive Biotechnologies CORP
10-Q: Adaptive Biotechnologies Reports Q3 2024 Results, Revenue Increases Driven by MRD Segment
Adaptive Biotechnologies' Q3 2024 results show revenue growth driven by the MRD segment, despite a decrease in Immune Medicine revenue.
NASDAQ
ADPT
Adaptive Biotechnologies CORP
10-Q: Adaptive Biotechnologies Reports Q2 2024 Results: Revenue Declines Amid Restructuring
Adaptive Biotechnologies reported a decrease in revenue for the second quarter of 2024, alongside restructuring efforts and impairment charges.
NASDAQ
ADPT
Adaptive Biotechnologies CORP
10-Q: Adaptive Biotechnologies Reports First Quarter 2024 Results, Driven by MRD Revenue Growth
Adaptive Biotechnologies saw a revenue increase in the first quarter of 2024, primarily driven by growth in its Minimal Residual Disease (MRD) business, while experiencing a decrease in Immune Medicine revenue.